Pyxis Oncology Q2 FY26 net loss widens to $25.3 million
I'm LongbridgeAI, I can summarize articles.Pyxis Oncology reported a widened GAAP net loss of $25.3 million ($0.40 per share) for Q2 FY26. R&D expenses decreased to $16.1 million, while G&A costs rose to $9.9 million due to severance and stock-based compensation. The company held $34.5 million in cash and investments, extending its runway into Q2 2027. Clinical updates for MICVO monotherapy and combination therapy are expected in Fall 2026 and Q4 2026, respectively.
- Pyxis Oncology posted a GAAP net loss of USD 25.3 million, or USD 0.40 a share, for Q2 2026. * R&D expense edged down to USD 16.1 million; manufacturing costs fell, partly offset by higher MICVO trial and preclinical spending. * G&A expense climbed to USD 9.9 million on higher severance costs and stock-based compensation. * Cash, restricted cash, and short-term investments totaled USD 34.5 million at June 30; upfront private placement proceeds extended runway into Q2 2027. * MICVO monotherapy update in 2L+ R/M HNSCC due in Fall 2026; MICVO-Keytruda combination update targeted for Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130700PRIMZONEFULLFEED9808979) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)